Company Overview and News

 
Summerset Group: Secular Growth And Lower Spending Support Long-Term Upside

4h seekingalpha
Valuing SMGRF can be tricky due to significant differences between the income and cash flow statements.
Upvote Downvote

 
Summerset Group: Secular Growth And Lower Spending Supports Long-Term Upside

5h seekingalpha
Valuing SMGRF can be tricky due to significant differences between the income and cash flow statements.
Upvote Downvote

 
NZ shares fall as MSCI changes debated

18h nzherald.co.nz
New Zealand shares fell, taking a negative lead from Wall Street, as Fletcher Building's share offer weighed on demand.
Upvote Downvote

 
NZ shares rise led by Synlait, A2, Comvita as US earnings stoke global sentiment

2018-04-19 nzherald.co.nz
New Zealand shares gained as the US earnings season helped lift sentiment toward equities. Growth-linked companies including Synlait Milk, A2 Milk, Comvita led gains in the local market.
Upvote Downvote

 
Shares fall as investors weight up Fletcher rights issue

2018-04-17 nzherald.co.nz
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.
Upvote Downvote

1
Shares fall as global tensions keep investors on the sidelines

2018-04-16 nzherald.co.nz
New Zealand shares fell in relatively subdued trading, led by Ebos Group, Ryman Healthcare, Air New Zealand and Fletcher Building. Comvita fell after a profit warning while A2 Milk gained on news of a deal in South Korea.
Upvote Downvote

 
NZ shares gain as President Xi Jinping speech lifts sentiment

2018-04-10 nzherald.co.nz
New Zealand shares rose as equity investors took heart from comments by Chinese President Xi Jinping that he favoured an open economy and lower tariffs. Pushpay Holdings, Ryman Healthcare, Air New Zealand, Trade Me and Australia & New Zealand Banking Group gained.
Upvote Downvote

 
Fletcher price slide sparks fears of index and investor exit

2018-04-08 nzherald.co.nz
Fletcher Building is trading at its lowest price in nearly a decade, sparking fears it could soon drop out of a key sharemarket index, which may well see big-time investors dump the stock.
Upvote Downvote

 
NZ sharemarket heads for third down day in a row

2018-03-25 nzherald.co.nz
The New Zealand sharemarket looks headed for its third down day after it opened 0.6 per cent lower following drops in the American markets on Friday.
Upvote Downvote

 
Global appetite for NZ yield stocks on pause, Harbour Asset's Bascand says

2018-03-25 nbr.co.nz
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.
Upvote Downvote

1
Global appetite for NZ yield stocks on'pause, Harbour Asset's Bascand says

2018-03-23 nbr.co.nz
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.
Upvote Downvote

 
Shares ease back from record high

2018-03-22 nzherald.co.nz
New Zealand shares were mixed, with Trustpower and Infratil both rising, while Heartland Bank and Freightways dropped.
Upvote Downvote

 
Brian Gaynor: New Xero boss has other fish to fry

2018-03-09 nzherald.co.nz
Rod Drury's resignation as Xero's chief executive this week was a huge surprise, as was the appointment of outsider Steve Vamos to replacement him.
Upvote Downvote

 
NZ shares fall; MetroGlass sinks to record low

2018-03-07 nzherald.co.nz
New Zealand shares fell as Metro Performance Glass sank to a record low on speculation it may drop out of the S&P/NZX 50 Index. Fisher & Paykel Healthcare, Fletcher Building and a2 Milk were among decliners while Kathmandu and Z Energy rose.
Upvote Downvote

 
Outrage from retirement giants over proposed government ban on foreign investors

2018-02-26 nzherald.co.nz
A proposed law change would ban multi-billion dollar retirement giants Ryman Healthcare and Metlifecare from buying any further New Zealand land, sparking an outcry from the NZX-listed businesses.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 78391Y108